Loading...
XTAE
KMDA
Market cap365mUSD
Apr 07, Last price  
2,232.00ILS
1D
-4.30%
1Q
2.37%
Jan 2017
12.86%
IPO
73.40%
Name

Kamada Ltd

Chart & Performance

D1W1MN
P/E
2,354.13
P/S
211.52
EPS
0.25
Div Yield, %
—
Shrs. gr., 5y
6.19%
Rev. gr., 5y
4.82%
Revenues
161m
+12.93%
13,437,19415,213,59314,979,71236,274,34155,920,91472,675,00070,623,00071,925,00070,113,00077,494,000102,825,000114,469,000127,187,000133,246,000103,642,000129,339,000142,519,000160,953,000
Net income
14m
+74.58%
00000260,000443,000-12,636,000-11,270,000-6,733,0006,901,00022,296,00022,251,00017,140,000-2,230,000-2,321,0008,284,00014,462,000
CFO
48m
+1,002.99%
00010,631,371940,357-8,262,000-3,854,000-9,918,000-13,979,0001,897,0003,890,00010,546,00027,571,00019,105,000-8,819,00028,586,0004,315,00047,594,000
Earnings
May 06, 2025

Profile

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
URL
https://www.kamada.com/
IPO date
Aug 01, 2005
Employees
380
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
160,953
12.93%
142,519
10.19%
129,339
24.79%
Cost of revenue
137,005
128,411
123,895
Unusual Expense (Income)
NOPBT
23,948
14,108
5,444
NOPBT Margin
14.88%
9.90%
4.21%
Operating Taxes
(1,128)
145
62
Tax Rate
1.03%
1.14%
NOPAT
25,076
13,963
5,382
Net income
14,462
74.58%
8,284
-456.92%
(2,321)
4.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,150
BB yield
-4.95%
Debt
Debt current
1,631
1,384
5,460
Long-term debt
20,493
16,260
18,333
Deferred revenue
Other long-term liabilities
53,971
53,855
55,514
Net debt
(56,311)
(46,422)
(18,062)
Cash flow
Cash from operating activities
47,594
4,315
28,586
CAPEX
(10,740)
(5,850)
(3,784)
Cash from investing activities
(10,739)
(5,843)
(3,784)
Cash from financing activities
(13,911)
22,678
(9,343)
FCF
23,129
(21,004)
37,736
Balance
Cash
78,435
55,641
34,258
Long term investments
8,425
7,597
Excess cash
70,387
56,940
35,388
Stockholders' equity
(13,785)
(28,378)
(39,980)
Invested Capital
338,282
335,076
292,114
ROIC
7.45%
4.45%
1.80%
ROCE
7.38%
4.60%
2.16%
EV
Common stock shares outstanding
54,793
53,676
44,815
Price
22.10
-0.76%
22.27
62.32%
13.72
-33.24%
Market cap
1,210,922
1.30%
1,195,354
94.41%
614,865
-33.17%
EV
1,154,611
1,148,932
596,803
EBITDA
37,756
27,019
17,599
EV/EBITDA
30.58
42.52
33.91
Interest
660
1,298
914
Interest/NOPBT
2.76%
9.20%
16.79%